Study to Assess the Dietary Carbohydrate Content of Indian Diabetics With Special Therapeutic View on Effectiveness of Acarbose and Metformin Monotherapy - STARCH AM

Bayer Zydus Pharma Private Ltd0 个研究点目标入组 12,250 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Drug-naÃ¯ve (i.e., the patients should never be treated with anti-diabetic drugs before screening) patients in whom decision to administer monotherapy with either acarbose or metformin for type-2 diabetes management has been made by the attending physician on the basis of best clinical practice and medical patient needs, and who consent to participate in study will be included

•Patients receiving any anti-diabetic medication at the time of enrollment in the study will be excluded. However, during observation period, patients may receive any additional anti-diabetics medication at the decision of investigator.
•Exclusion criteria should be read in conjunction with local product information. All contra-indications according to the local marketing authorization should be considered

发起方

Bayer Zydus Pharma Private Ltd